Introduction
Several lines of evidence point to the important role of JAK2V617F (VF), which is found in X90% of polycythemia vera (PV), and 50% of primary myelofibrosis and essential thrombocythemia (ET) patients, in the pathogenesis of BCR-ABLnegative myeloproliferative neoplasms (MPNs). 1, 2 It was surprising, however, that a single disease allele would be associated with these three distinct, though overlapping, clinical phenotypes. There are at least three possible explanations, with varying degrees of experimental support, for this apparent paradox: the disease phenotype may be influenced by the concomitant presence of other disease alleles (for example, MPL, TET2, ASXL1 mutations), [3] [4] [5] [6] differences in the ratio of mutant VF relative to wild-type JAK2, 7 or presence of hostmodifying factors. 8 With regard to the latter, familial MPN studies have suggested the presence of heritable alleles that predispose to the development of these disorders. 9, 10 Using a candidate gene approach, we previously identified several JAK2 single-nucleotide polymorphisms (SNPs) exhibiting high linkage disequilibrium that were significantly associated with PV and ET; we also identified JAK2 haplotypes that were significantly associated with PV only. 8 Although PV is characterized by a high rate of acquired uniparental disomy (aUPD) at chromosome 9p, 11 which causes allelic distortions and reduces VF to homozygosity in clonal cells, the aforementioned JAK2 SNPs and haplotypes maintained their significant association with MPN phenotype, despite an accounting for VF mutational status in our statistical model. More recently, several groups have identified a particular JAK2 haplotype, designated '46/1' or 'GGCC', which is strongly associated with the development of VF-positive MPN. [12] [13] [14] Furthermore, in these studies, the VF mutation was found to be preferentially acquired in cis with the 46/1 haplotype (in 74-85% of cases), thereby suggesting a direct interaction between a specific haplotype in the JAK2 locus and secondary acquisition of the VF mutation as the major mechanism for VF-positive MPN predisposition and pathogenesis.
In this study, we genotyped 226 ET patients, for whom complete clinical information was available with relatively long follow-up, at tagged SNP rs12343867, which is in complete linkage disequilibrium with JAK2 46/1 haplotype. Our objectives were: (i) to assess whether 46/1 is enriched in ET patients as compared with population controls; (ii) to assess whether 46/1 is distributed differently in VF-positive versus VF-negative ET, and to study its association with VF allele burden; and (iii) to determine possible associations between 46/1 and clinical features.
Materials and methods
The study was approved by the Mayo Clinic Institutional Review Board. All patients provided authorization for use of their medical records for research purposes, and research was carried out according to the principles of the Declaration of Helsinki. We used the Mayo Clinic database of adult ET patients (age X18 years) to identify consecutive patients in whom stored bone marrow (BM) cells were available for DNA extraction. Clinical data and BM histology were re-reviewed and the diagnosis of ET was confirmed as per the 2008 World Health Organization proposal. 15 The VF allele burden assay was carried out using DNA from BM-derived cells according to previously published methods. 16 In order to screen for the JAK2 46/1 haplotype, we genotyped rs12343867 SNP, which is in complete linkage disequilibrium with the 46/1 haplotype, 12 using a commercially available TaqMan SNP genotyping assay (Applied Biosystems Inc., Foster City, CA, USA).
Data analysis was carried out on parameters collected at the time of initial diagnosis. JAK2 46/1 haplotype allele frequencies in the study population (n ¼ 226) were compared with those of both local (n ¼ 57) and population controls (n ¼ 1500) from the Wellcome Trust Case Control Consortium (WTCCC), using w 2 statistics. 12 Statistical procedures utilized were conventional and all data were analyzed using StatView (SAS Institute, Cary, NC, USA). All P-values were two-tailed and statistical significance was set at the level of Po0.05. The Fisher's exact test or w 2 -test for 2 Â 2 contingency tables and Mann-Whitney U-test or Kruskal-Wallis test were used to test for differences in proportions of nominal variables and medians of continuous variables, respectively. Actuarial probability of survival was estimated using the Kaplan-Meier product-limit method. Overall survival was defined as the time between diagnosis and death (as a result of all causes) or end of follow-up (censored observations). Comparison between Kaplan-Meier curves were carried out by the log-rank test. Cox regression model was used for multivariable analysis.
Results
We studied 226 consecutive ET patients (145 females; median age ¼ 57 years; range ¼ 14-91 years); clinical characteristics are described in Table 1 . In all, 41 patients (18%) had a history of arterial and/or venous thrombosis at diagnosis, and 26 (12%) had a leukocyte count X15 Â 10 9 per liter. A total of 118 patients (52%) were VF positive and the median VF allele burden in BM cells was 7% (range 1-68%); of these, 21 patients (18%) had a VF allele burden of 410%. After a median followup of 7.4 years (range o1-33.2 years), 56 patients (25%) had died; 54 (24%) developed thrombosis during follow-up, and 17 (8%) and 10 (4%) experienced disease transformation to myelofibrosis and acute leukemia, respectively. Consistent with previous reports, VF-positive patients were significantly older and exhibited higher hemoglobin and leukocyte count, but lower platelet count, as compared with VF-negative patients. [17] [18] [19] Survival was similar in VF-positive and -negative patients; the appearance of an association between high VF allele burden and inferior survival was accounted for by age. 18 As previously noted, venous thrombosis during follow-up was more frequently observed in VF-positive patients. 18 In this ET cohort (n ¼ 226), SNP rs12343867genotype distributions were CC (15%), CT (52%) and TT (33%) ( Tables 1  and 2 ). JAK2 haplotype 46/1, as tagged by the 'C' allele at the aforementioned SNP, occurred significantly more frequently in ET patients (185 of 452 alleles; 41%) as compared with 1500 healthy blood donors from the United Kingdom genotyped at this locus by the WTCCC (720 of 3000 alleles; 24%) (Po0.01; odds ratio (OR) ¼ 2.2; 95% confidence interval (CI) ¼ 1.8-2.7). Similarly, the 'C' allele also occurred significantly more frequently in the ET cohort as compared with 57 healthy local controls (32 of 114 alleles; 28%) (P ¼ 0.01; OR ¼ 1.8; 95% CI ¼ 1.1-2.8). SNP rs12343867 genotype distribution, as stratified by VF mutation status, is shown in Tables 1 and 2 .There was The clinical and laboratory parameters of the study patients stratified by rs12343867 SNP genotype are presented in Table 3 . The distribution of age (P ¼ 0.71), sex (P ¼ 0.18) or prognosisrelevant clinical parameters, including hemoglobin level (P ¼ 0.47), leukocyte count X15 Â 10 9 per liter (P ¼ 0.14), or occurrence of thrombosis either at diagnosis (P ¼ 0.49) or during follow-up (P ¼ 0.15), were not significantly influenced by rs12343867 genotype. The only significant association noted was, as elaborated in the above paragraph, with high VF allele burden (Po0.01). Neither the rate of disease transformation to myelofibrosis (P ¼ 0.08) or acute leukemia (P ¼ 0.64), nor overall survival (P ¼ 0.21; Figure 1 ) was correlated with rs12343867 genotype.
Discussion
Although three recent studies have convincingly shown a significant association between the JAK2 46/1 haplotype and VF-positive MPN, [12] [13] [14] several issues remain to be clarified. First, it is unclear whether the 46/1 haplotype is significantly associated with VF-negative MPN. Two of the aforementioned studies did not find a significant association between 46/1 and VF-negative MPN, 13, 14 whereas the third study yielded mixed results. 12 In the latter, 46/1 was significantly enriched relative to population controls in 47 UK cases of VF-negative ET/myelofibrosis; however, in an independent population of 136 Greek cases of VF-negative ET, no such enrichment of 46/1 was evident. Second, the frequency and VF-stratified distribution of 46/1 in large representative cohorts of individual MPNs have not clearly definedFin published reports to date, MPN cases were culled from multiple centers, and frequently, PV and ET cases were lumped together for the analysis. Third, the clinical correlates of 46/1, including its relationship to VF allele burden, remain to be elucidated.
In this study, we used a large representative cohort of 226 ET patients for whom complete clinical information and mature follow-up data were available. ET patients are well suited for association studies, given the low frequency of aUPD as compared with PV patients, 20 which minimizes confounding allelic distortions when studying clonal cells. In this study, we found 46/1 to be significantly enriched in ET patients as compared with the control population (41 vs 24%). In contrast to previous reports, 13, 14 we found the incidence of 46/1 in VF-positive (44%) and -negative ET patients (38%) was not significantly different. We have previously shown that ET patients harbor a population of cells with homozygous VF. 21 A unique feature of this study was the availability of VF allele burden data, which, at high levels, can serve as a surrogate for aUPD at chromosome 9p, and can be used to control for allelic distortion effects relating to the same. We found 46/1 to occur significantly more frequently in the presence of 410% VF allele burden as compared with VF-negative cases, but the haplotype frequency was similar when comparing patients with VF allele burden p10% to VF-negative cases. Possible explanations for the apparently more pronounced 46/1 association in VF-positive cases include allelic distortion from aUPD-associated allele duplication and the higher likelihood of inaccurate diagnosis among VF-negative cases, in the absence of a clonal marker, which could weaken the particular association in that context. A similar scenario was also evident in a separate group of 130 patients with primary myelofibrosis (see the accompanying article by Tefferi et al 22 ). It remains possible, however, that a larger study of ET patients may reveal a small but significant association of 46/1 with VF-positive ET even after accounting for the aforementioned potential confounding effects. The clinical Table 2 Relationship between JAK2 46/1 haplotype as tagged by the 'C' allele at single-nucleotide polymorphism genotype rs12343867 and JAK2V617F (VF) mutational status in 226 patients with essential thrombocythemia Abbreviations: ET, essential thrombocythemia; N, number; VF, JAK2V617F. *P1, P-value for genotype (CC/CT/TT) comparisons; P2, P-value for C-allele frequency comparisons; P3, P-value for comparison of C-allele frequency with that of control population (Wellcome Trust Case Control Consortium controls in which the C-allele frequency was reported at 24%; n ¼ 1500).
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Abbreviations: Dx, diagnosis; f/u, follow-up; Hgb, hemoglobin; plt, platelet; Tx, transformation; VF, JAK2V617F mutation; WBC, white blood cell; y, years; %, percentage of total cases in each category.
JAK2 haplotype 46/1 in ET A Pardanani et al phenotype of 46/1-positive and -negative ET was indistinguishable in the present cohortFblood counts, rate of thrombosis or disease transformation and overall survivalFwere similar for both groups. Other prognostically relevant variables, such as age at diagnosis, presence of anemia and leukocyte count X15 Â 10 9 per liter, were also similarly distributed among the two groups. 23 Overall, using ET as a model, our data do not directly support the 'hyper mutability' hypothesis that posits presence of a specific mutational mechanism, perhaps predilection to DNA damage, favoring secondary acquisition of VF and JAK2 exon 12 mutations, 24 in the context of a specific JAK2 haplotype (that is, 46/1). Instead, given that MPN development is not restricted to cases in which the VF mutation arises in cis with 46/1, our data support the alternate hypothesis, whereby 46/1 is linked to a (yet uncharacterized) functional JAK2 variant that interacts with VF or an alternative disease allele in a manner that allows clonal expansion and makes development of clinically manifest disease more likely. Obviously, the aforementioned does not exclude a possible specific functional interaction between 46/1 and VF that underlies the significantly greater occurrence of both in cis. Regardless, more studies with larger number of patients will be needed to confirm the findings in this report. 
